YKL-40 in patients with end-stage renal disease receiving haemodialysis.

Autor: Nielsen TL; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Plesner LL; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Warming PE; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Pallisgaard JL; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Dalsgaard M; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Schou M; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Høst U; b Medical Department , Glostrup Hospital, Rigshospitalet University of Copenhagen , Copenhagen , Denmark., Rydahl C; c Department of Nephrology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Brandi L; d Department of Cardiology, Endocrinology and Nephrology , North Zealand Hospital University of Copenhagen , Copenhagen , Denmark., Køber L; e Department of Cardiology , Rigshospitalet University of Copenhagen , Copenhagen , Denmark., Johansen JS; f Departments of Medicine and Oncology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark., Kastrup J; e Department of Cardiology , Rigshospitalet University of Copenhagen , Copenhagen , Denmark., Iversen KK; a Department of Cardiology , Herlev Hospital University of Copenhagen , Copenhagen , Denmark.
Jazyk: angličtina
Zdroj: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2018 May - Jun; Vol. 23 (4), pp. 357-363. Date of Electronic Publication: 2018 Mar 08.
DOI: 10.1080/1354750X.2018.1428359
Abstrakt: Purpose: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.
Methods: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.
Results: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL -1 (IQR: 193-291 µgL -1 ) before HD treatment and 198 µgL -1 (IQR: 147-258 µgL -1 ) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.
Conclusion: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje